Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"… Read more
Elicio Therapeutics Inc. (ELTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -2.905x
Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has a cash flow conversion efficiency ratio of -2.905x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.09 Million) by net assets ($3.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Elicio Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Elicio Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Elicio Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elicio Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
-0.189x |
|
PROTALIX BIOTHERAP.DL-01
F:PBDA
|
N/A |
|
Hes Technology Group
SHE:002963
|
0.053x |
|
PowerCell Sweden AB (publ)
PINK:PCELF
|
0.016x |
|
Benchmark Metals Inc
V:CEI
|
0.029x |
|
CAMP4 THERAPEUTICS CORPORATION
NASDAQ:CAMP
|
0.132x |
|
Jiangsu Teeyer Intelligent Equipment Co.,Ltd.
SHG:603273
|
-0.011x |
|
Ginebra San Miguel Inc
PINK:GBSMF
|
0.001x |
Annual Cash Flow Conversion Efficiency for Elicio Therapeutics Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Elicio Therapeutics Inc. from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-11.31 Million | $-37.07 Million | 3.277x | +213.99% |
| 2023-12-31 | $11.37 Million | $-32.69 Million | -2.875x | -15.55% |
| 2022-12-31 | $8.91 Million | $-22.18 Million | -2.488x | -747.05% |
| 2021-12-31 | $81.51 Million | $-23.94 Million | -0.294x | -216.07% |
| 2020-12-31 | $-90.45 Million | $-22.89 Million | 0.253x | -80.87% |
| 2019-12-31 | $-18.59 Million | $-24.59 Million | 1.323x | +411.96% |
| 2018-12-31 | $18.91 Million | $-8.02 Million | -0.424x | -199.94% |
| 2013-12-31 | $4.46 Million | $1.89 Million | 0.424x | +68.83% |
| 2012-12-31 | $4.24 Million | $1.07 Million | 0.251x | -- |